Skip to main content

Alterity Therapeutics Ltd

ATHE
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001131343

In the last 90 days, Alterity Therapeutics Ltd insiders filed 1 open-market purchase and 0 sales; 21 institutions reported holding it in 13F filings for Q2 2026, worth $2.12M in total; no superinvestor holds it.

Other share classesPRNAF

Holders of 5% or more of ATHE

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Alterity Therapeutics Ltd, largest stake first. The change is against the holder's previous filing.

No holder currently reports owning 5% or more of Alterity Therapeutics Ltd on Schedule 13D or 13G.

Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.

13D and 13G filings

2 Schedule 13D and 13G filings on Alterity Therapeutics Ltd, newest first, including old-format filings without a stake.

Schedule 13D and 13G filings on ATHE
Filed (ET)FilerFormStakeChangeEvent dateFiling
May 5, 20252:03 PM ETJPMorgan Chase & Co13G/A4.00%366.0M shares−2.30 ppfrom 6.30%Below 5%Apr 30, 2025SEC
May 2, 20259:59 AM ETJPMorgan Chase & Co13G6.30%429.7M sharesNewMar 31, 2025SEC

Form 144: proposed insider sales

Notices from officers, directors and other affiliates planning to sell Alterity Therapeutics Ltd shares.

No Form 144 notices for Alterity Therapeutics Ltd are on file.